Table 3.
Sample Sizes, Methylation Means and Standard Deviations by Race, Stage, Extra Thyroidal Extension and FTC type
| Race: AA versus CA | Variable | AA (N= 14) | CA (N= 34) | p-value |
|---|---|---|---|---|
| RASSF1 | 14 (0.637 ± 0.531) | 34 (0.422 ± 0.702) | 0.054 | |
| DAPK1 | 14 (0.000 ± 0.000) | 34 (0.001 ± 0.003) | 0.61 | |
| ESR1 | 14 (0.000 ± 0.001) | 34 (0.005 ± 0.015) | 0.575 | |
| Stage: Early vs Late | Early (N= 36) | Late (N= 15) | ||
| AGE | 36 (51.4 ± 13.0) | 15 (66.7 ± 13.6) | <.001 | |
| DAPK1 | 36 (0.000 ± 0.000) | 15 (0.001 ± 0.005) | 0.034 | |
| ESR1 | 36 (0.000 ± 0.001) | 15 (0.017 ± 0.038) | 0.035 | |
| RASSF1 | 36 (0.419 ± 0.511) | 15 (0.634 ± 0.777) | 0.877 | |
| Extra Thyroidal Extension | No Extension (N= 41) | Extension Present (N= 6) | ||
| DAPK1 | 41 (0.000 ± 0.000) | 6 (0.003 ± 0.007) | 0.014 | |
| ESR1 | 41 (0.002 ± 0.008) | 6 (0.036 ± 0.057) | 0.036 | |
| RASSF1 | 41 (0.470 ± 0.602) | 6 (0.703 ± 0.693) | 0.306 | |
| FTC Hurthle vs FTC Classic | FTC Hurthle (N= 26) | FTC Classic (N= 27) | ||
| RASSF1 | 26 (0.340 ± 0.751) | 27 (0.730 ± 0.605) | <.001 | |
| DAPK1 | 26 (0.001 ± 0.004) | 27 (0.000 ± 0.000) | 0.159 | |
| ESR1 | 26 (0.001 ± 0.002) | 27 (0.011 ± 0.030) | 0.154 |
AA - African American; CA - Caucasian American; Early Stage - Stages 1, 2, and Unknown; Late Stage - Stages 3 and 4; FTC - Follicular Thyroid Cancer